WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Least developed GNI / capita (US$): 6301 Infant (under 12 months) mortality rate: 572
GDP / capita (US$): 1'1691 Child (under 5 years) mortality rate: 792

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 27'978  27'216  26'467  25'733  25'017  18'265  13'372  11'936 
Births 1'087  1'070  1'053  1'035  1'018  822  629  568 
Surviving infants 1'021  1'004  986  968  950  740  540  483 
Pop. less than 5 years 4'816  4'724  4'633  4'540  4'445  3'332  2'409  2'172 
Pop. less than 15 years 12'675  12'387  12'091  11'786  11'475  8'210  6'334  5'256 
Female 15-49 years 6'448  6'256  6'073  5'899  5'736  4'359  3'024  2'789 

Number of reported cases

(Click for retrospective incidence data for Mozambique)
Diphtheria
ChartChart
  11 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  79  145  177  7'375  18'082  30'070 
Mumps
ChartChart
 
Pertussis
ChartChart
  94  451 
Polio*
ChartChart
  65 
Rubella
ChartChart
  210  127  428  143 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  271  59  47  42  34  101 
Tetanus (total)**
ChartChart
  281  59  110  60  65  102  573 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Mozambique)
Vaccine year result method % card seen                                                
BCG 2010  91  DHS   83  95  94  93  91  91  99*  59 
DTP1 2010  91  DHS   83  90  93  93  91  91  99* 
DTP3 2010  76  DHS   83  80  88  78  76  76  88  46 
DTP4         
IPV1          93 
HepB_BD         
HepB3          80  88  78  76  76 
Hib3          80  88  78  76  76 
JapEnc         
MCV1          85  87  85  82  82  97  59 
MCV2         
PCV1          90  91  80 
PCV3          80  88  60 
Pol3 2010  73  DHS   83  80  88  78  73  73  87  46 
Rota1          99* 
RotaC          59 
Rubella1         
TT2plus 2010  56  DHS   83  80  66  64  70  70  61  21 
PAB         
VAD1          66  59  60 
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Mozambique)
BCG
ChartChart
  95  94  93  91  91  84  59 
DTP1
ChartChart
  90  92  93  91  91  84  71 
DTP3
ChartChart
  80  79  78  76  76  70  46 
HepB3
ChartChart
  80  79  78  76  76 
HepB_BD
ChartChart
 
Hib3
ChartChart
  80  79  78  76  76 
IPV1
ChartChart
 
MCV1
ChartChart
  85  85  85  82  82  71  59 
MCV2
ChartChart
 
PAB
ChartChart
  83  83  83  83  83  75  37 
PCV3
ChartChart
  80  73  45 
Pol3
ChartChart
  80  79  78  73  73  69  46 
RCV1
ChartChart
 
RotaC
ChartChart
  17 

Number of districts in the country 148  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 68
From 80 to 89% 18
From 50 to 79% 14
Less than 50% 1
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 6, 10, 14 weeks; Yes
HPV 1, 6 months; No
IPV 14 weeks; Yes
MR 9, 18 months; From October 2017
Measles 9, 18 months; Yes
OPV 6, 10, 14 weeks; Yes
Pneumo_conj 6, 10, 14 weeks; Yes
TT 1st contact; +1, +6 months; +1, +1 year; Yes
VitaminA 6, 12, 18, 24, 30, 36 months;

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2015-2019  2014-2018  2014-2018  2012-2016  2012-2016  2009-2013  2009 - 2013 
Nº of districts with microplans that include activities to raise immunization coverage number 148  148  148  148  144  66  66 

System performance

Total Nº districts in country number 148  148  148  148  144  144  144 
Nº districts with DTP3 coverage >=80% number 127  130  128  136  98  43  118 
% of districts with DTP3 coverage >=80% From 0 to 100% 86  88  86  92  68  30  82 
Nº districts with measles (MCV1) coverage >=95% number 55  67  44  63  42  70  76 
% of districts with MCV1 coverage >=95% From 0 to 100% 37  45  30  43  29  49  53 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  No  No  No  No   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR No  Yes  No  No  No  No  No 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 20    23  34  24  25  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  No   

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.